Pioglitazone decreases postprandial accumulation of remnant lipoproteins in insulin-resistant smokers

Diabetes, Obesity and Metabolism

Volumn 11, Issue 8, 2009, Pages 779-785

  Abbasi, Fahim ^a   Lamendola, C ^a   Leary, E T ^b   Reaven, G M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Pacific Biometrics Inc   (United States)

Author keywords

Insulin resistance; Pioglitazone; Postprandial lipaemia; Remnant lipoproteins; Smoking

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE INCREASE; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; LIPOPROTEIN BLOOD LEVEL; MALE; NORMAL HUMAN; POSTPRANDIAL STATE; RISK REDUCTION; SMOKING; STEADY STATE; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

CARDIOVASCULAR DISEASES; CHOLESTEROL; FASTING; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; SMOKING; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 67649961523     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01041.x     Document Type: Article

References (38)

1. Zilversmit DB. Atherogenesis: A postprandial phenomenon. Circulation 1979; 60: 473-485.
2. Simons LA, Dwyer T, Simons J et al. Chylomicrons and chylomicron remnants in coronary artery disease: A case-control study. Atherosclerosis 1987; 65: 181-189.
3. Simpson HS, Williamson CM, Olivecrona T et al. Postprandial lipemia, fenofibrate and coronary artery disease. Atherosclerosis 1990; 85: 193-202.
4. Groot PH, van Stiphout WA, Krauss XH et al. Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. Arterioscler Thromb 1991; 11: 653-662.
5. Patsch JR, Miesenbock G, Hopferwieser T et al. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler Thromb 1992; 12: 1336-1345.
6. Karpe F, Bard JM, Steiner G, Carlson LA, Fruchart JC, Hamsten A. HDLs and alimentary lipemia. Studies in men with previous myocardial infarction at a young age. Arterioscler Thromb 1993; 13: 11-22.
7. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
8. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-316.
9. Chen YD, Reaven GM. Intestinally-derived lipoproteins: Metabolism and clinical significance. Diabetes Metab Rev 1991; 7: 191-208.
10. Chen YD, Swami S, Skowronski R, Coulston AM, Reaven GM. Effect of variations in dietary fat and carbohydrate intake on postprandial lipemia in patients with noninsulin dependent diabetes mellitus. J Clin Endocrinol Metab 1993; 76: 347-351.
11. Jeppesen J, Chen YI, Zhou MY, Schaaf P, Coulston A, Reaven GM. Postprandial triglyceride and retinyl ester responses to oral fat: effects of fructose. Am J Clin Nutr 1995; 61: 787-791.
12. Jeppesen J, Hollenbeck CB, Zhou MY et al. Relation between insulin resistance, hyperinsulinemia, postheparin plasma lipoprotein lipase activity, and postprandial lipemia. Arterioscler Thromb Vasc Biol 1995; 15: 320-324.
13. Abbasi F, McLaughlin T, Lamendola C et al. Fasting remnant lipoprotein cholesterol and triglyceride concentrations are elevated in nondiabetic, insulin-resistant, female volunteers. J Clin Endocrinol Metab 1999; 84: 3903-3906.
14. Ai M, Tanaka A, Ogita K et al. Relationship between hyperinsulinemia and remnant lipoprotein concentrations in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2000; 85: 3557-3560.
15. Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 2007; 9: 640-647.
16. Stumvoll M, Haring HU. Glitazones: Clinical effects and molecular mechanisms. Ann Med 2002; 34: 217-224.
17. Willett W, Hennekens CH, Castelli W et al. Effects of cigarette smoking on fasting triglyceride, total cholesterol, and HDL-cholesterol in women. Am Heart J 1983; 105: 417-421.
18. Facchini FS, Hollenbeck CB, Jeppesen J, Chen YD, Reaven GM. Insulin resistance and cigarette smoking. Lancet 1992; 339: 1128-1130.
19. Reaven G, Tsao PS. Insulin resistance and compensatory hyperinsulinemia: the key player between cigarette smoking and cardiovascular disease? J Am Coll Cardiol 2003; 41: 1044-1047.
20. Abbasi F, Farin HM, Lamendola C et al. The relationship between plasma adiponectin concentration and insulin resistance is altered in smokers. J Clin Endocrinol Metab 2006; 91: 5002-5007.
21. Farin HM, Abbasi F, Kim SH, Lamendola C, McLaughlin T, Reaven GM. The relationship between insulin resistance and dyslipidaemia in cigarette smokers. Diabetes Obes Metab 2007; 9: 65-69.
22. Abbasi F, Farin HM, Lamendola C, McGraw L, McLaughlin T, Reaven GM. Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers. Metabolism 2008; 57: 1108-1114.
23. Pei D, Jones CN, Bhargava R, Chen YD, Reaven GM. Evaluation of octreotide to assess insulin-mediated glucose disposal by the insulin suppression test. Diabetologia 1994; 37: 843-845.
24. Shen SW, Reaven GM, Farquhar JW. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. J Clin Invest 1970; 49: 2151-2160.
25. Greenfield MS, Doberne L, Kraemer F, Tobey T, Reaven G. Assessment of insulin resistance with the insulin suppression test and the euglycemic clamp. Diabetes 1981; 30: 387-392.
26. Yeni-Komshian H, Carantoni M, Abbasi F, Reaven GM. Relationship between several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. Diabetes Care 2000; 23: 171-175.
27. Lamendola C, Abbasi F, Chu JW et al. Comparative effects of rosuvastatin and gemfibrozil on glucose, insulin, and lipid metabolism in insulin-resistant, nondiabetic patients with combined dyslipidemia. Am J Cardiol 2005; 95: 189-193.
28. Leary ET, Wang T, Baker DJ et al. Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma. Clin Chem 1998; 44: 2490-2498.
29. Nakajima K, Saito T, Tamura A et al. Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels. Clin Chim Acta 1993; 223: 53-71.
30. Craig WY, Palomaki GE, Haddow JE. Cigarette smoking and serum lipid and lipoprotein concentrations: An analysis of published data. BMJ 1989; 298: 784-788.
31. Eliasson B, Mero N, Taskinen MR, Smith U. The insulin resistance syndrome and postprandial lipid intolerance in smokers. Atherosclerosis 1997; 129: 79-88.
32. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992; 70: 733-737.
33. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96: 2520-2525.
34. Goldberg RB. Impact of thiazolidenediones on serum lipoprotein levels. Curr Atheroscler Rep 2006; 8: 397-404.
35. Kannel WB. Update on the role of cigarette smoking in coronary artery disease. Am Heart J 1981; 101: 319-328.
36. Ockene IS, Miller NH. Cigarette smoking, cardiovascular disease, and stroke: A statement for healthcare professionals from the American Heart Association. American Heart Association Task Force on Risk Reduction. Circulation 1997; 96: 3243-3247.
37. Jeppesen J, Hein HO, Suadicani P, Gyntelberg F. Low triglycerides-high high-density lipoprotein cholesterol and risk of ischemic heart disease. Arch Intern Med 2001; 161: 361-366.
38. Chu JW, Abbasi F, Kulkarni KR et al. Multiple lipoprotein abnormalities associated with insulin resistance in healthy volunteers are identified by the vertical auto profile-II methodology. Clin Chem 2003; 49: 1014-1017.